ClinicalTrials.gg
RecruitingNCT04503395SOCRATESUpdated May 22, 2026

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

An interventional study of ESAR treatment: Endograft + Heli-FX Endoanchor and FEVAR treatment : Fenestrated endograft in Aortic Aneurysm, Abdominal, sponsored by FCRE (Foundation for Cardiovascular Research and Education). Recruiting at 33 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by FCRE (Foundation for Cardiovascular Research and Education) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Aortic Aneurysm, Abdominal with a site in United States — 28 open to participants now, 34 under way, 1 of them phase 3. Aortic Aneurysm, Abdominal · United States.

Planned enrollment
25th of 85
204 · median 94
Started
2021
with 6 others
No phase
64 of 122
14 open now
Primary completion
2026-06
later than 3 of 33 live
Registered
93rd of 122
by date

Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, this one is the 25th largest by planned enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2021, is one of 64 with no phase, reaches primary completion later than 3 of the 33 other live ones, and was the 93rd registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

28 of the 122 studies in Aortic Aneurysm, Abdominal with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Aortic Aneurysm, Abdominal with a site in United States, or all of them as a file.
02

Study summary

The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).

03

Conditions studied

  • Aortic Aneurysm, Abdominal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is >18 years old
  • Subject is scheduled for primary treatment of the abdominal aortic aneurysm with a non-aneurysmal infrarenal aortic sealing zone proximal to the aneurysm that is sufficiently healthy for a proximal neck length that is at least 4mm and not more than15 mm and has a circumferential minimum sealing zone length of 8 mm
  • Subject is not a candidate for safe, effective and durable standard EVAR due to challenging anatomical criteria as confirmed by the Core Lab screening
  • Subject is able and willing to comply with the protocol and to adhere to the follow-up requirements.
  • Subject has provided written

CT Angiographic Inclusion Criteria

  • Subject meets the other anatomical requirements according to the locally applicable Endurant II/IIs stent graft system, Heli-FX EndoAnchor system, Terumo Fenestrated Anaconda (available in EU only) and/or Cook Zenith Fenestrated Graft Instructions for Use
  • Proximal neck length of the aorta within 4-15mm and a minimum circumferential sealing zone of 8mm
  • Aortic neck diameter from 19 to 31mm
  • Infrarenal neck angulation ≤45°

Exclusion criteria

Exclusion Criteria:

  • Subject is participating in a concurrent study which may confound study results
  • Subject has a \<2 year
  • Subject is female of in whom pregnancy cannot be excluded
  • Subject with \<30 mL/min/m2 (KDOQI classification - exclude class IV and above) and or on dialysis
  • Subject with a MI or CVA within 3 months prior to index procedure
  • Subject with known Connective Tissue Disease
  • Subject has a known or to anticoagulants, antiplatelets, or contrast media, which is not amenable to post-treatment
  • Subject who has undergone prior endovascular or open surgical treatment for abdominal aortic aneurysm
  • Subject requires emergent aneurysm treatment, for example, trauma or rupture
  • Subject has a known hypersensitivity or allergies to study device implant material
  • Subject has an aneurysm that is:

    • Suprarenal, pararenal, or thoracoabdominal
    • Mycotic
    • Inflammatory
    • Pseudoaneurysm
  • Subject is presenting with thrombus or calcification of the proximal aneurysm neck: circumferential >50%
  • Pre-op stenosis of the renal arteries > 50%
  • Subject has active infection or history of COVID-19. History of COVID-19 is defined as availability of positive COVID-19 test with sequelae or hospitalization for treatment of COVID-19.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    ESAR

    Endovascular Aneurysm Repair + Heli-FX EndoAnchors

    Device: ESAR treatment: Endograft + Heli-FX Endoanchor

  • Active comparator
    FEVAR

    Fenestrated EndoVascular Aneurysm Repair

    Device: FEVAR treatment : Fenestrated endograft

Interventions

  • DeviceESAR treatment: Endograft + Heli-FX Endoanchor

    ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor

  • DeviceFEVAR treatment : Fenestrated endograft

    Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft

06

What researchers measure

Primary outcomes

  1. Effectiveness Endpoint - Technical Success

    Composite of technical success at index procedure, and freedom from type IA or type III endoleak, freedom from aneurysm related mortality (ARM), and freedom from secondary reinterventions through 12 months post index procedure.

    Time frame: through 12 months post-procedure

  2. Safety Endpoint - Freedom from Major Adverse Events

    Freedom from MAE through 30 days post index procedure. MAE defined as: All-Cause-Mortality, Bowel Ischemia, Myocardial Infraction, Procedural Blood Loss \> 1000cc, Access related complications, permanent paraplegia and paraparesis at 30 days, disabling stroke, respiratory failure, or renal complications

    Time frame: through 30 days post-procedure

Secondary outcomes

  1. Total contrast volume (ml) at index procedure

    Total contrast volume (mL) at index procedure

    Time frame: at index procedure

  2. Total fluoroscopy time (minutes) at index procedure

    Total fluoroscopy time (minutes) at index procedure

    Time frame: at index procedure

  3. Duration (minutes) of index procedure

    3\. Duration (minutes) of index procedure (time between initial skin access to final closure of the last artery access site)

    Time frame: at index procedure

  4. Adequate penetration of EndoAnchor implants as assessed by the Core Lab

    Adequate penetration of EndoAnchor implants as assessed by the Core Lab

    Time frame: at index procedure

  5. Clinical success

    7\. Clinical success defined as technical success + freedom from intra-operative death and freedom from type IA/III endoleak in the first post-op image within 30 days.

    Time frame: through 30 days post-procedure

  6. Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up

    Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up

    Time frame: through 1,12,24 and 36-months post-op

  7. Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up

    Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up

    Time frame: through 1,12,24 and 36-months post-op

  8. Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up

    Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up

    Time frame: through 1,12,24 and 36-months post-op

  9. Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up

    Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up

    Time frame: through 1,12,24 and 36-months post-op

  10. Freedom from stent graft migration (>10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up

    Freedom from stent graft migration (\>10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up

    Time frame: through 12,24 and 36-months post-op

  11. Sac dynamics (>5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up

    Sac dynamics (\>5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up

    Time frame: through 12,24 and 36-months post-op

  12. Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up

    Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up

    Time frame: through 1,12,24 and 36-months post-op

  13. Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up

    Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up

    Time frame: through 1,12,24 and 36-months post-op

  14. Overall SCI rate, include transient events at 1 and 12 months follow-up

    Overall SCI rate, include transient events at 1 and 12 months follow-up

    Time frame: through 1 and 12 months post-op

  15. Freedom from aortic neck-related secondary interventions

    reinterventions for Type IAa endoleak, migration of the proximal stent graft, and progression of disease in the infrarenal aortic neck; progression of disease is defined as enlargement of the infrarenal aortic neck compared to the first postprocedural CT scan, as measured by either diameter, surface and/or volume.

    Time frame: at 1-, 12-, 24- and 36-months follow-up

07

Study locations

28 of 33 sites recruiting
  • UCSD Medical Center Hillcrest
    La Jolla, California 92037, United States
    Recruiting
  • Stanford University
    Stanford, California 94305, United States
    Recruiting
    • Jason Lee · Contact
  • University of Florida
    Gainesville, Florida 32608, United States
    Recruiting
  • Corewell Health (Spectrum)
    Grand Rapids, Michigan 49503, United States
    Recruiting
  • Mount Sinai Hospital
    New York, New York 10029, United States
    Recruiting
    • Rami Tadros · Contact
  • Oklahoma Heart
    Tulsa, Oklahoma 74104, United States
    Recruiting
    • Adel Barkat · Contact
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
    Recruiting
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 14212, United States
    Recruiting
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
    Recruiting
    • Hosam El-Sayed · Contact
  • Hospital Ottakring, Institute for Vascular Surgery
    Vienna, 1160, Austria
    Recruiting
    • Afshin Assadian · Contact
  • CRC thoracic Vascular Surgery, ZOL Genk
    Genk, 3600, Belgium
    Recruiting
    • Wouter Lansink, Dr MD · Contact
  • Universitair Ziekenhuis Gent, Thoracale en vasculaire heelkunde
    Ghent, 9000, Belgium
    Recruiting
    • Isabelle vanHerzeele · Contact
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
    Recruiting
    • Du Pont · Contact
  • Amrois Paré Hospital (APHP)
    Boulogne, France
    Recruiting
    • Raphael Coscas · Contact
  • Service de Chirurgie Vasculaire et Endovasculaire CHU Gabriel-Montpied 58 rue Montalembert
    Clermont-Ferrand, 63003, France
    Recruiting
    • Fabien Thaveau · Contact
  • Hospices Civils de lyon - Hôpital Edouard Herriot
    Lyon, France
    Recruiting
    • Antoine Millon · Contact
  • Centre Hospitalier Universitaire de Rennes
    Rennes, France
    Recruiting
    • Adrien Kaladji · Contact
  • University Hospital RWTH Aachen
    Aachen, 52074, Germany
    Recruiting
    • Alexander Gombert · Contact
  • University Hospital Leipzig
    Leipzig, 04109, Germany
    Recruiting
    • Dierk Scheinert · Contact
  • Klinikum der Technischen Universität München
    München, 81675, Germany
    Recruiting
    • Branzan · Contact
  • Martin Austermann
    Münster, 48145, Germany
    Completed

    Not enrolling at this site — choose another above.

  • University of Bologna, IRCCS S. Orsola Hospital,
    Bologna, 40138, Italy
    Recruiting
    • Mauro Gargiulo, Prof · Contact
  • Az. Ospedaliera San Martino, Genova
    Genova, 16132, Italy
    Recruiting
    • Giovanni Pratesi · Contact
  • IRCCS Ospedale San Raffaele, Chirurgia Vascolare
    Milan, 20132, Italy
    Recruiting
    • Andrea Kahlberg, Prof · Contact
  • Vascular Endovascular Surgery University of Perugia;
    Perugia, 06100, Italy
    Not yet recruiting
    • Massimo Lenti, Prof MD · Contact
    • Giacomo Isernia, MD, PHD · Contact
  • Az.Osped.Univers.S.Giovanni, Turin
    Turin, 10154, Italy
    Recruiting
    • Fabio Verzini · Contact
  • Azienda Ospedaliera Universitaria Integrata di Verona
    Verona, Italy
    Recruiting
    • Veraldi · Contact
  • VUMC Amsterdam
    Amsterdam, Netherlands
    Not yet recruiting
    • Kak Khee Yeung · Contact
  • Catharina Ziekenhuis
    Eindhoven, Netherlands
    Not yet recruiting
    • Philippe Cuypers · Contact
  • National Institute of Cardiology Warzwa
    Warsaw, 04-628, Poland
    Recruiting
    • Piotr Szopinski · Contact
  • Hospital Ramon Y Cajal
    Madrid, Spain
    Recruiting
    • Andrés Reyer · Contact
  • HOSPITAL CLINICO UNIVERSITARIO Valladolid
    Valladolid, 47003, Spain
    Recruiting
    • Lourdes del Rio Sola · Contact
  • Inselspital Bern, Universitätsklinik für Gefässchirurgie
    Bern, 3010, Switzerland
    Not yet recruiting
    • Drosos Kotelis, Prof · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Jun 2026, 60 months after the start.

Of 51 non-industry interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's planned 60 months is above that.

Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Aug 7, 2020
StartActual
May 21, 2021
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2032
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04503395
Lead sponsor
FCRE (Foundation for Cardiovascular Research and Education)
Collaborators
Medtronic
Responsible party
Marc Bosiers, MD (Sponsor, FCRE (Foundation for Cardiovascular Research and Education)) — Principal investigator
First posted
Aug 7, 2020
Start date
May 21, 2021
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2032 (estimated)
Last update
May 22, 2026

Study contacts

Karlotta Knuth
Contact
info@fcre.eu
+4915785318893
Giovanni Torsello, Prof. Dr.
principal investigator · Vascupedia
Brant Ullery, MD, MBA
principal investigator · Medical Director, Vascular Surgery Providence Heart and Vascular Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion